Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey A multicenter prospective surveillance study

Basit Öğe Kaydı
dc.contributor.authorCeyhan, Mehmet
dc.contributor.authorGurler, Nezahat
dc.contributor.authorOzsurekci, Yasemin
dc.contributor.authorKeser, Melike
dc.contributor.authorAycan, Ahmet Emre
dc.contributor.authorGurbuz, Venhar
dc.contributor.authorSalman, Nuran
dc.date.accessioned2020-03-26T18:51:28Z
dc.date.available2020-03-26T18:51:28Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractSuccessful vaccination policies for protection from bacterial meningitis are dependent on determination of the etiology of bacterial meningitis. Cerebrospinal fluid (CSF) samples were obtained prospectively from children from 1 month to <= 18 years of age hospitalized with suspected meningitis, in order to determine the etiology of meningitis in Turkey. DNA evidence of Neisseria meningitidis (N. meningitidis), Streptococcus pneumoniae (S. pneumoniae), and Hemophilus influenzae type b (Hib) was detected using multiplex polymerase chain reaction (PCR). In total, 1452 CSF samples were evaluated and bacterial etiology was determined in 645 (44.4%) cases between 2005 and 2012; N. meningitidis was detected in 333 (51.6%), S. pneumoniae in 195 (30.2%), and Hib in 117 (18.1%) of the PCR positive samples. Of the 333 N. meningitidis positive samples 127 (38.1%) were identified as serogroup W-135, 87 (26.1%) serogroup B, 28 (8.4%) serogroup A and 3 (0.9%) serogroup Y; 88 (26.4%) were non-groupable. As vaccines against the most frequent bacterial isolates in this study are available and licensed, these results highlight the need for broad based protection against meningococcal disease in Turkey.en_US
dc.description.sponsorshipNovartis Vaccines and Diagnostics; GlaxoSmithKlineGlaxoSmithKlineen_US
dc.description.sponsorshipThe study was supported by Novartis Vaccines and Diagnostics (for 5 years) and by GlaxoSmithKline (for 2 years). The authors declare that they have no other conflicts of interest.en_US
dc.identifier.doi10.4161/hv.29678en_US
dc.identifier.endpage2712en_US
dc.identifier.issn2164-5515en_US
dc.identifier.issn2164-554Xen_US
dc.identifier.issue9en_US
dc.identifier.pmid25483487en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2706en_US
dc.identifier.urihttps://dx.doi.org/10.4161/hv.29678
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30981
dc.identifier.volume10en_US
dc.identifier.wosWOS:000348316800043en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS INCen_US
dc.relation.ispartofHUMAN VACCINES & IMMUNOTHERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectMeningitisen_US
dc.subjectTurkeyen_US
dc.subjectetiologic agentsen_US
dc.subjectN. meningitidisen_US
dc.subjectS. pneumoniaeen_US
dc.subjectHiben_US
dc.subjectepidemiologyen_US
dc.subjectsurveillanceen_US
dc.titleMeningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey A multicenter prospective surveillance studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu